Kampmeyer Daniela, Haas Christian Stefan, Moenig Heiner, Harbeck Birgit
Department of Medicine I, University of Luebeck, Luebeck, Germany.
Department of Medicine I, Christian-Albrechts-University, Kiel, Germany.
Endocr J. 2017 Apr 29;64(4):379-385. doi: 10.1507/endocrj.EJ16-0429. Epub 2017 Feb 10.
Patients with adrenal insufficiency (AI) require life-long glucocorticoid (GC) replacement treatment and dose adjustment in stress situations to prevent life-threatening adrenal crises. Herein this study we evaluated the patients' healthcare situation and their knowledge on AI, comparing various aspects to a prior survey in 209 physicians. Using a questionnaire, we conducted a comprehensive survey among 33 AI patients who were treated at the endocrine outpatient clinics of two University Hospitals in Germany. The majority of AI patients (97%) named their treating physician as main source for information. Overall, 89.7% of interviewees were satisfied with their medical treatment; however, about 1/3 reported controversies with healthcare professionals regarding GC replacement in various situation. Two thirds of AI patients increased their substitution dose temporarily within the last 12 months. However, not all patients had an emergency ID, and only 64.5% an emergency kit. None of the interviewed patients identified the need for adjustment in all given situations correctly. Almost 80% of patients did not correctly identify all symptoms of GC over- and under-replacement. Interestingly, we found no significant differences between patients and physicians regarding specific aspects of GC replacement. We showed that: (i) AI patients have some knowledge gaps on modalities and adequacy of GC replacement therapy; (ii) long-term management of patients with AI remains a challenge requiring an experienced specialist; and (iii) further education of physicians as primary source of information is necessary. Additional education may help AI patients to empower them to adequate self-treatment.
肾上腺功能不全(AI)患者需要终生接受糖皮质激素(GC)替代治疗,并在应激情况下调整剂量,以预防危及生命的肾上腺危象。在本研究中,我们评估了患者的医疗状况及其对AI的认知,并将各个方面与之前对209名医生的调查进行了比较。我们通过问卷调查对德国两家大学医院内分泌门诊治疗的33名AI患者进行了全面调查。大多数AI患者(97%)将其主治医生列为主要信息来源。总体而言,89.7%的受访者对其医疗治疗感到满意;然而,约1/3的受访者报告在各种情况下与医护人员在GC替代方面存在争议。三分之二的AI患者在过去12个月内曾临时增加替代剂量。然而,并非所有患者都有急救身份标识,只有64.5%的患者有急救包。在接受采访的患者中,没有人能正确识别在所有给定情况下的调整需求。近80%的患者没有正确识别GC替代过量和不足的所有症状。有趣的是,我们发现患者和医生在GC替代的具体方面没有显著差异。我们表明:(i)AI患者在GC替代治疗的方式和充分性方面存在一些知识空白;(ii)AI患者的长期管理仍然是一项挑战,需要经验丰富的专家;(iii)有必要对作为主要信息来源的医生进行进一步教育。额外的教育可能有助于AI患者有能力进行充分的自我治疗。